Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:35:04 2024-06-12 pm EDT 5-day change 1st Jan Change
147.1 USD -0.88% Intraday chart for Moderna, Inc. -4.79% +48.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Raises Price Target on Moderna to $96 From $85 MT
Oppenheimer Raises Price Target on Moderna to $179 From $163 MT
Moderna Insider Sold Shares Worth $30,087,339, According to a Recent SEC Filing MT
Health Care Up on Defensive Bias -- Health Care Roundup DJ
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Retreat Monday Afternoon MT
Sector Update: Health Care MT
Transcript : Moderna, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM
Top Midday Stories: Elliott Amasses $2 Billion Stake in Southwest; SCOTUS to Review Meta Investor Data-Harvesting Suit; Blackstone Competes Tropical Smoothie Acquisition MT
Moderna's Combination Flu, COVID-19 Shot Triggers High Immune Responses in Late-stage Study MT
Moderna's Combined Influenza, COVID-19 Shot Elicits 'Higher Immune Response' Versus Others, Drugmaker Says MT
Exchange-Traded Funds, Equity Futures Retreat Pre-Bell Monday Ahead of Key Economic Data, FOMC Announcement MT
Moderna: phase 3 trial of an experimental vaccine CF
Moderna Says Combination Vaccine Shows Higher Immune Response Against Flu, Covid-19 in Phase 3 Trial MT
Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19 CI
Moderna COVID/flu combo vaccine superior to separate shots in trial RE
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 RE
Moderna Files With FDA for Updated Covid Shot DJ
Moderna Files US FDA Application for Spikevax 2024-2025 Formula MT
Moderna Seeks US Approval for JN.1 Variant-focused COVID-19 Jab MT
COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says RE
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine CI
Jefferies Adjusts Price Target on Moderna to $180 From $155, Keeps Buy Rating MT
Moderna: experimental treatment selected by the FDA CF
S&P 500, Nasdaq dip on the eve of US payrolls data RE
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.4 USD
Average target price
145.2 USD
Spread / Average Target
-2.17%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Sector Update: Health Care Stocks Slipping Late Afternoon